<DOC>
	<DOCNO>NCT00296218</DOCNO>
	<brief_summary>Primary Objective - The main objective study ass two-month regimen irbesartan patient hospitalize acute coronary syndrome without ST segment elevation reduce inflammation marker ( ie hsCRP ) , comparison similar regimen enalapril . Secondary Objectives - To compare regimens several biological parameter demonstrate relevance predictive clinical value ( ie BNP , microalbuminuria , troponin I … ) patient population . - To compare parameter early initiation treatment versus initiation treatment hospital discharge .</brief_summary>
	<brief_title>ARCHIPELAGO : Irbesartan Patients With Acute Coronary Syndrome Without ST Segment Elevation</brief_title>
	<detailed_description />
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Irbesartan</mesh_term>
	<criteria>The following information clinical trial provide information purpose allow patient physician initial discussion trial . This information intend complete information trial , contain consideration may relevant potential participation trial , replace advice personal physician health professional . Main criterion list hereafter : Inclusion Criteria Patient hospitalise ischemic symptom ( last episode within last 48 hour randomization ) least one follow characteristic NSTEACS ( nonSTsegmentelevation acute coronary syndrome ) : ECG ST T change ( ST depression transient elevation least 1mm T wave change least 2 lead ) Positive troponin ( accord local threshold ) Exclusion Criteria Women child bear potential unwilling unable use acceptable method avoid pregnancy entire study period 4 week study WOCBP use prohibit contraceptive method ( applicable ) Women pregnant breast feed Women positive pregnancy test enrolment prior study drug administration Patient dementia Persistent ST segment elevation ECG Systolic blood pressure &lt; 100 mmHg Bilateral stenosis renal artery Creatinine clearance &lt; = 30ml/mn Congestive heart failure symptom consistent New York Heart Association ( NYHA ) class III IV . Aortic mitral valve stenosis Hypertrophic cardiomyopathy Connective tissue disease vascular involvement Angioplasty , surgery trauma within last 3 month Coronarography angioplasty plan perform performed baseline sample Febrile ( ≥ 38°C ) disease , know concomitant viral bacterial infection , chronic auto immune disease , chronic inflammatory disease , know cancer evolution Hyperkalemia : serum potassium &gt; 5.5mmol/l Sensitivity intolerance Angiotensin receptor blocker ( ARBs ) : olmesartan , candesartan , irbesartan , eprosartan , losartan , telmisartan , valsartan and/or ARB currently previously development . Sensitivity intolerance Angiotensinconverting Enzyme Inhibitors ( ACEI ) : benazepril , captopril , enalapril , lisinopril , trandolapril , ramipril , quinapril , and/or ACEI currently previously development . Chronic steroid nonsteroidal anti inflammatory drug ( NSAIDs ) use . Aspirin permit . Treatment allopurinol procaïnamide Concomitant use potassium spar diuretic ( eg . spironolactone , triamterene amiloride ) , potassium preparation salt substitute contain potassium Treatment Lithium Immunosupressive medication Administration investigational drug last 30 day enrolment course study Treatment ARB ACE inhibitor within last 3 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
</DOC>